Kiniksa Pharmaceuticals International, plcKNSAEarnings & Financial Report
Nasdaq
NextFeb 27, 2026
KNSA Q3 2025 Key Financial Metrics
Revenue
$180.9M
Gross Profit
$160.6M
Operating Profit
$24.0M
Net Profit
$18.4M
Gross Margin
88.8%
Operating Margin
13.3%
Net Margin
10.2%
YoY Growth
61.2%
EPS
$0.23
Financial Flow
Kiniksa Pharmaceuticals International, plc Q3 2025 Financial Summary
Kiniksa Pharmaceuticals International, plc reported revenue of $180.9M for Q3 2025, with a net profit of $18.4M (10.2% margin). Cost of goods sold was $20.3M, operating expenses totaled $136.6M.
Key Financial Metrics
| Total Revenue | $180.9M |
|---|---|
| Net Profit | $18.4M |
| Gross Margin | 88.8% |
| Operating Margin | 13.3% |
| Report Period | Q3 2025 |
Kiniksa Pharmaceuticals International, plc Annual Revenue by Year
Kiniksa Pharmaceuticals International, plc annual revenue history includes year-by-year totals (for example, 2024 revenue was $423.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $423.2M |
| 2023 | $270.3M |
| 2022 | $220.2M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $83.4M | $79.9M | $108.6M | $112.2M | $122.5M | $137.8M | $156.8M | $180.9M |
| YoY Growth | 34.8% | 65.2% | 52.0% | 67.4% | 46.9% | 72.5% | 44.3% | 61.2% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $526.3M | $519.7M | $542.4M | $555.3M | $580.6M | $599.3M | $661.1M | $712.3M |
| Liabilities | $87.5M | $87.8M | $107.3M | $118.3M | $142.1M | $141.8M | $166.1M | $176.9M |
| Equity | $438.8M | $431.9M | $435.1M | $437.0M | $438.4M | $457.5M | $495.0M | $535.4M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $4.3M | $4.0M | $5.2M | $-2.2M | $18.8M | $22.3M | $28.1M | $33.7M |